Gregory J. Crane, M.D. is an assistant professor of medicine at the University of Kansas School of Medicine. Dr. Crane earned his medical degree from the SUNY University at Buffalo. He subsequently went onto complete his internal medicine residency at Drexel University/Hahnemann Hospital in Philadelphia and fellowship at University of Medicine and Dentistry of New Jersey at Cooper University Hospital in Camden, New Jersey. He is board certified by the American Board of Internal Medicine with sub-certifications in Oncology. He has an interest in head and neck cancer, GI cancers and uveal melanoma. He is also active as a board member in the Kansas Society of Clinical Oncology. Outside of work, he has a wife and 2 daughters who enjoy hiking, camping, and traveling.

Dr. Joseph A. Moore received his medical degree from the University of Kansas School of Medicine. He completed his Internal Medicine residency at the University of Texas Southwestern Medical Center in Dallas, TX. Subsequently, he completed his fellowship in Hematology and Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, serving as Chief Oncology fellow in his final year. He returned to Wichita to join the Cancer Center of Kansas (CCK) team in 2021. In joining CCK, Dr. Moore becomes a third generation oncologist and hematologist to serve Kansas and CCK patients following the footsteps of his grandfather, Dr. Dennis Moore, Sr. and his father Dr. Dennis Moore, Jr.

During his training at MD Anderson Cancer Center, Dr. Moore received numerous honors and awards including the MD Anderson LBJ 3rd Year Fellow of the Year, as well as the MD Anderson Cancer Center Education Fellow Excellence Award for Teamwork. Dr. Moore is board certified in Internal Medicine, Medical Oncology and Hematology. He is a member of the American Society of Clinical Oncology, American Society of Hematology, American Society for Transplantation and Cellular Therapy, American College of Physicians and Alpha Omega Alpha. Dr. Moore is committed to clinical cancer research and has numerous academic abstracts and publications.

Isaac Chambers, MD, received his medical degree from the University of Kansas School of Medicine, Wichita in 2014. He completed his internal medicine training at the University of Kansas School of Medicine, Wichita in 2017. He was awarded the Mahlon H. Delp Award which recognizes the most outstanding internal medicine resident.

Dr. Chambers then completed a three-year fellowship in hematology/oncology at the University of Iowa in 2020. He served as the chief follow his final two years of fellowship. Dr. Chambers is board-certified in internal medicine, medical oncology, and hematology. He is a member of the American Society of Clinical oncology, American Society of Hematology, American College of Physicians, and Alpha Omega Alpha. Dr. Chambers currently practices medical oncology and hematology in Hays Kansas where he also participates as a clinical investigator for the Masonic Cancer Alliance.

Quoc Truong, MD, received his medical degree from the University of Kansas School of Medicine in 2001. He completed his internal medicine/pediatrics residency at the University of Kansas School of Medicine – Wichita, and then worked as a hospitalist at Wesley Medical Center from 2005 to 2010. Subsequently, he completed a three-year fellowship in hematology and medical oncology at West Virginia University before returning to Wichita to join the Cancer Center of Kansas team in 2013.

Dr. Truong is board certified in internal medicine, hematology, and medical oncology. He is a member of the American Society of Clinical Oncology, American Society of Hematology, and American Society for Blood and Marrow Transplantation. Dr. Truong is committed to clinical cancer research as a principal investigator of the Wichita NCI Community Oncology Research Program. He also serves the Wichita community in his role as a member of The Leukemia & Lymphoma Society Board of Directors.

As director of plasma cell disorders care at The University of Kansas Health System and chair of the US Myeloma Innovations of Research Collaborative (USMIRC), Dr. Al-Ola Abdallah is primarily focused on managing and treating patients with various plasma cell disorders, including myeloma, AL amyloidosis, POEMS, solitary plasmacytoma, MGUS and smoldering myeloma. Additionally, he runs many clinical trials regarding PCD and has developed a multidisciplinary amyloidosis program that involves nephro-oncology, cardio-oncology, neurology and palliative care.

His interest in myeloma began when he joined the Myeloma Institute for Research and Therapy (MIRT) at the University of Arkansas for Medical Sciences as an assistant professor of medicine. Working as a clinician and research subinvestigator in multiple tasks of the treatment protocol, Dr. Abdallah gained a solid foundation of knowledge in chemotherapy administration, mechanism of action, HPC collection and infusion, engraftment, treatment of complications and toxicities, and management of expected side effects.

His experience at MIRT went beyond the clinical aspect. It allowed him the opportunity to witness and participate in each of his patient’s journey with cancer, which was a humbling experience. He was honored to care for them through the difficult and rewarding challenges that come with a cancer diagnosis.

Overall, Dr. Abdallah’s passion for treating myeloma and plasma cell disorders stems from his desire to help patients navigate the complexities of these diseases and provide them with the best possible care. Through his work at the health system, the University of Kansas Medical Center and USMIRC, he strives to collaborate with community oncologists to develop best practices and ultimately improve outcomes for patients.

Dr. Ammar Al-Obaidi earned his medical degree from Al-Nahrain University in 2006 and worked as an internal medicine provider in Iraq and Jordan until 2012. That year, he moved to Houston, Texas, joining MD Anderson’s research department. He later transitioned to medical oncology and hematology, completing his residency at the University of Kansas School of Medicine in 2021 and becoming board certified in internal medicine. Dr. Al-Obaidi then completed a fellowship at the University of Missouri-Kansas City with distinction and joined the Cancer Center of Kansas in 2024. He also became board certified in medical oncology and hematology by the American Board of Internal Medicine in 2024.

A committed researcher, Dr. Al-Obaidi has authored over a dozen manuscripts and abstracts focused on cancer advancements and treatment outcomes. He is affiliated with leading professional, medical organizations such as the American Society of Hematology, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. Outside of his practice, he enjoys spending time with his family and participating in soccer, billiards, and swimming.

Dr. Elie Chalhoub is a hematologist and medical oncologist with experience in providing expert care to cancer patients. With a career of over 7 years, Dr. Chalhoub demonstrates a commitment to advancing cancer treatment and patient well-being. He obtained his medical degree from the Lebanese University in 2009. In 2013, Dr. Chalhoub completed his Internal Medicine Residency at the University of Kansas School of Medicine in Wichita, where he served as Chief Resident. During his residency, he won several awards, including Intern of the Year, Outstanding Resident of the Year (PGY2), WC Goodpasture Resident Performance Award, and the Linda Francisco Peer Teaching Award. During his Hematology/Oncology fellowship at Tulane University, Dr. Chalhoub excelled and was named Chief Fellow, demonstrating his commitment to leadership and excellence in patient care.

Gary Doolittle, MD, is the Capitol Federal Masonic Professor of Medicine in the Division of Oncology at the University of Kansas Medical Center, where he is also Medical Director of the Masonic Cancer Alliance, vice-chair of education in the Department of Internal Medicine and Assistant Dean for the Office of Medical Education.

Dr Doolittle has been a faculty member in the Division of Clinical Oncology at KU for 30 years—he has a subspecialty interest in the treatment of malignant melanoma. He has written many journal articles, books, and book chapters on a range of oncology topics, with a major emphasis on telemedicine in cancer care delivery. Dr. Doolittle serves as the contact PI for the KUCC MCA MU NCORP grant and serves as Co-I for the recently awarded Early Therapeutics Cancer Trials Network Grant. Both grants were written to extend cancer clinical trials to the rural sector in the state of Kansas and western Missouri.

Dr. Doolittle earned his medical degree from the University of Kansas Medical Center, where he also completed a residency in internal medicine and a fellowship in hematology/oncology.

Dr. Jeffrey Holzbeierlein is physician in chief at The University of Kansas Cancer Center and the William L. Valk Endowed Professor at the University of Kansas Medical Center. He specializes in the treatment of genitourinary malignancies including bladder, kidney, testicular and penile cancers. His research interests include the Hsp90 inhibitors in bladder cancer and clinically decreasing the morbidity associated with cystectomy.

Dr. Holzbeierlein was raised in Edmond, Oklahoma, and received his undergraduate degree from Vanderbilt University. He earned his medical degree at the University of Oklahoma and completed his internship and residency at Vanderbilt University. He joined the faculty at the medical center after he completed his fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center, New York.

Dr. Holzbeierlein is on the executive board of directors and is a past president of the south-central section of the American Urological Association. He is president for the Society of Urologic Oncology and is past chair of the fellowship committee and serves on the executive board of the SUO. For this work, he received the SUO Distinguished Service Award in 2013.

Dr. Holzbeierlein has served on the American Board of Urology Oncology knowledge assessment examination committee and is a past assistant editor for the Journal of Urology. He currently is a member of the oral boards committee for the American Board of Urology and has served on numerous AUA committees, including the practice guidelines committee and the public media committee, and he has completed the AUA Leadership Program.

He has been on the steering committee for the American Society of Clinical Oncology Genitourinary Cancers and is also the past chair and founding member of the young urologic oncologists section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Cancer and Urologic Oncology. He has also been awarded the Resident Mentoring Award for faculty at The University of Kansas Hospital.

Dr. Holzbeierlein has published numerous peer-reviewed journal articles and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA course focusing on the management of high-risk bladder cancer that was selected as one of the “best courses” at the AUA. He has intramural and extramural grant support, including a co-investigator role on an R01, and he is the principal investigator on a SWOG trial.

He lives in Kansas City with his wife, Jill, and their 4 children.

Dr. Joseph McGuirk is certified by the American Board of Internal Medicine with a subcertification in medical oncology. He completed a fellowship at Yale New Haven Hospital. He earned his medical degree from the University of Health Sciences College of Osteopathic Medicine and completed his residency at Yale New Haven Hospital.

I am a medical oncologist who is focused on head and neck and thoracic oncology. I am also the director of the hematology-oncology fellowship and co-chair of the head and neck disease working group. The area of research is clinical research in head and neck oncology. I started my career as a clinician and several years of general hematology-oncology practice in a small community hospital.